Dmitry Balyasny’s Atara Biotherapeutics ATRA Stock Holding History

Dmitry Balyasny’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,339	Closed	-$221K	–	2767
2022 Q3	$221K	Buy	2,339 +1,592	+213%	+$179K	﹤0.01%	2287
2022 Q2	$146K	Buy	+747	New	+$122K	﹤0.01%	2237

Other funds holding ATRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dmitry Balyasny's ATRA Position: Q4 2022 in Review

Dmitry Balyasny sold out of Atara Biotherapeutics (ATRA) in Q4 2022, closing a stake of 2,339 shares — an estimated $221K sold.

Dmitry Balyasny first reported a position in ATRA in Q2 2022 and held it in 2 quarters. The position peaked at $221K in Q3 2022. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2022.

Dmitry Balyasny reported no remaining Atara Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Dmitry Balyasny sold 2,339 Atara Biotherapeutics shares in Q4 2022, an estimated $221K.
Dmitry Balyasny first reported a position in Atara Biotherapeutics in Q2 2022 and held it in 2 quarters.
Dmitry Balyasny's Atara Biotherapeutics position peaked at $221K in Q3 2022.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.